# Phase I Study of Mitoxantrone Hydrochloride Liposome Injection

> **NCT02131688** · PHASE1 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Malignant Lymphoma

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome

## Key facts

- **NCT ID:** NCT02131688
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2015-08
- **Final completion:** 2015-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2014-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02131688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02131688, "Phase I Study of Mitoxantrone Hydrochloride Liposome Injection". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02131688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*